How to Help Your Patients Save Money on Hemgenix: A Provider's Guide to Savings Programs

At a list price of approximately $3.5 million per one-time dose, Hemgenix (etranacogene dezaparvovec-drlb) can seem financially inaccessible. Yet for the majority of commercially insured patients, the actual out-of-pocket burden is near zero — if providers know how to navigate the available financial support infrastructure. This guide is designed to help hematologists, HTC staff, and care coordinators understand the full landscape of savings programs and coverage pathways for Hemgenix in 2026.

How Hemgenix Is Billed: Medical Benefit, Not Pharmacy Benefit

This distinction is critical for financial planning. Hemgenix is billed under the medical benefit — specifically as a provider-administered drug under the medical benefit or hospital outpatient benefit, not as a pharmacy claim. This means:

Prior authorization is submitted through the medical/utilization management pathway, not the pharmacy benefit manager (PBM)

The infusion facility (HTC or hospital) submits the claim; it does not go through a retail or specialty pharmacy

Patient cost-sharing (deductible, coinsurance, out-of-pocket maximum) applies to the medical benefit, not the prescription benefit

Some plans may process this as a "buy and bill" claim where the facility purchases and administers the drug and then bills the payer

Understanding this billing model is essential for coordinating coverage and copay support for patients.

HEMGENIX Connect: The Primary Support Program for Providers and Patients

HEMGENIX Connect (1-833-436-0021, M–F 8AM–8PM ET) is CSL Behring's hub program that provides comprehensive support to both patients and their healthcare teams. As a provider, enrolling your patient in HEMGENIX Connect as early as possible in the treatment decision process is the single most important action to take for financial support.

What HEMGENIX Connect provides:

CSL Case Manager: Investigates coverage, determines benefits, submits prior authorization support, identifies financial assistance eligibility, and helps coordinate the infusion scheduling process.

Copay Support Program: Covers eligible commercially insured patients' cost-sharing for Hemgenix (copays, deductibles, coinsurance). Most commercially insured patients have $0 out-of-pocket cost for the infusion itself.

Patient Resource Navigator: Provides patient education about gene therapy, treatment journey support, and connection to the Hemgenix Patient Advocate Program (patients connected with others who have received Hemgenix).

Treatment center locator: Identifies the nearest in-network certified Hemgenix administration center for your patient's insurance plan.

Insurance Prior Authorization: What Payers Typically Require

Providers submitting PA requests for Hemgenix should anticipate needing the following clinical documentation:

Confirmed hemophilia B diagnosis with documented Factor IX activity levels (moderately severe to severe: FIX ≤2% for severe; FIX 2–5% for moderate-severe)

Documentation of current FIX prophylaxis use or qualifying bleeding history (recurrent serious bleeds, or life-threatening hemorrhage)

Negative Factor IX inhibitor titers (<0.6 Bethesda Units) — must be documented from a validated assay

Baseline liver function tests (ALT, AST, bilirubin) within normal limits or minimally elevated

Letter of medical necessity from treating hematologist including risk-benefit discussion

AAV5 neutralizing antibody test result (CSL Behring provides and covers this test at no cost to patient or provider)

Navigating Denials and Appeals

Initial PA denials do occur for Hemgenix, particularly when documentation is incomplete. Best practices for handling denials:

Request the specific denial reason in writing — insurance companies are required to provide this.

Submit first-level internal appeal within the insurer's deadline (typically 30–60 days from denial).

For medical necessity denials: include peer-reviewed literature supporting Hemgenix, the FDA label, and clinical notes documenting the burden of prophylaxis on your patient.

Utilize the HEMGENIX Connect Case Manager to support appeal documentation — they have expertise in this process and access to payer-specific criteria.

Medicare Coverage for Hemgenix

Hemgenix is covered under Medicare Part B for eligible beneficiaries with hemophilia B who meet coverage criteria. As a Part B drug administered by a healthcare provider, Medicare pays 80% of the Medicare-approved amount after the beneficiary meets their Part B deductible. The 20% coinsurance may be covered by Medicare Supplement (Medigap) plans. Medicare Advantage plans have their own PA requirements — verify coverage and in-network requirements before scheduling.

Note: CSL Behring's Copay Support Program is not available to patients covered by government insurance programs (Medicare, Medicaid, VA/TRICARE). These patients should be directed to the HEMGENIX Connect Case Manager for alternative financial assistance pathways and foundation resources.

Additional Financial Resources for Patients

National Bleeding Disorders Foundation: Patient assistance program directory; advocacy for insurance coverage; financial emergency assistance.

Hemophilia Federation of America — Helping Hands Program: Emergency financial crisis assistance for people with bleeding disorders; available once per year.

Coalition for Hemophilia B: Insurance navigation support and advocacy.

For a patient-facing guide to saving money on Hemgenix, share How to Save Money on Hemgenix in 2026 with your patients. Providers can also visit medfinder.com/providers to learn how medfinder helps care teams navigate specialty medication access.